The effects of the oral supplementation of L‐Cystine associated with reduced L‐Glutathione‐GSH on human skin pigmentation: a randomized, double‐blinded, benchmark‐ and placebo‐controlled clinical trial
Background Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter...
Saved in:
Published in | Journal of cosmetic dermatology Vol. 21; no. 2; pp. 802 - 813 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.02.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 1473-2130 1473-2165 1473-2165 |
DOI | 10.1111/jocd.14137 |
Cover
Abstract | Background
Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect.
Aims
To evaluate the skin lightening and anti‐dark spot effects of oral supplementation with L‐Cystine associated with L‐Glutathione as compared to placebo and benchmark.
Methods
Effects of this L‐Cystine‐L‐Glutathione oral combination were investigated in a 12‐week randomized, double‐blind, parallel‐group, benchmark‐ and placebo‐controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L‐Cystine and 250 mg L‐Glutathione, 250 mg reduced L‐Glutathione, 500 mg L‐Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs.
Results
A significant skin lightening was observed after 12 weeks of oral supplementation with L‐Cystine associated with L‐Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L‐Cystine alone or L‐Glutathione alone.
Conclusion
The daily oral administration of 500 mg L‐Cystine and 250 mg L‐Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women. |
---|---|
AbstractList | Glutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect.BACKGROUNDGlutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect.To evaluate the skin lightening and anti-dark spot effects of oral supplementation with L-Cystine associated with L-Glutathione as compared to placebo and benchmark.AIMSTo evaluate the skin lightening and anti-dark spot effects of oral supplementation with L-Cystine associated with L-Glutathione as compared to placebo and benchmark.Effects of this L-Cystine-L-Glutathione oral combination were investigated in a 12-week randomized, double-blind, parallel-group, benchmark- and placebo-controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L-Cystine and 250 mg L-Glutathione, 250 mg reduced L-Glutathione, 500 mg L-Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs.METHODSEffects of this L-Cystine-L-Glutathione oral combination were investigated in a 12-week randomized, double-blind, parallel-group, benchmark- and placebo-controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L-Cystine and 250 mg L-Glutathione, 250 mg reduced L-Glutathione, 500 mg L-Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs.A significant skin lightening was observed after 12 weeks of oral supplementation with L-Cystine associated with L-Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L-Cystine alone or L-Glutathione alone.RESULTSA significant skin lightening was observed after 12 weeks of oral supplementation with L-Cystine associated with L-Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L-Cystine alone or L-Glutathione alone.The daily oral administration of 500 mg L-Cystine and 250 mg L-Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women.CONCLUSIONThe daily oral administration of 500 mg L-Cystine and 250 mg L-Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women. Background Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect. Aims To evaluate the skin lightening and anti‐dark spot effects of oral supplementation with L‐Cystine associated with L‐Glutathione as compared to placebo and benchmark. Methods Effects of this L‐Cystine‐L‐Glutathione oral combination were investigated in a 12‐week randomized, double‐blind, parallel‐group, benchmark‐ and placebo‐controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L‐Cystine and 250 mg L‐Glutathione, 250 mg reduced L‐Glutathione, 500 mg L‐Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs. Results A significant skin lightening was observed after 12 weeks of oral supplementation with L‐Cystine associated with L‐Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L‐Cystine alone or L‐Glutathione alone. Conclusion The daily oral administration of 500 mg L‐Cystine and 250 mg L‐Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women. Glutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been considered to explain this property, one of them being the skewing of the melanin synthesis pathway toward the production of lighter pheomelanin instead of darker eumelanin, consequently producing a lightening effect. To evaluate the skin lightening and anti-dark spot effects of oral supplementation with L-Cystine associated with L-Glutathione as compared to placebo and benchmark. Effects of this L-Cystine-L-Glutathione oral combination were investigated in a 12-week randomized, double-blind, parallel-group, benchmark- and placebo-controlled trial involving 124 Asian female subjects. Women were randomly allocated into 4 equal groups (500 mg L-Cystine and 250 mg L-Glutathione, 250 mg reduced L-Glutathione, 500 mg L-Cystine, or a placebo, daily). Skin color was measured at baseline, after 6 and 12 weeks by spectrophotometry. Size and color of facial dark spots were determined from digital photographs. A significant skin lightening was observed after 12 weeks of oral supplementation with L-Cystine associated with L-Glutathione. This combination also induced a significant reduction in the size of facial dark spots after 6 and 12 weeks. It is noteworthy that the observed effects were not only significantly better than those obtained with placebo, but also with L-Cystine alone or L-Glutathione alone. The daily oral administration of 500 mg L-Cystine and 250 mg L-Glutathione during 12 weeks was a safe treatment to effectively lighten the skin and reduce the size of facial dark spots of Asian women. |
Author | Chalothorn, Kunyanatt Duperray, Joël Sergheraert, Renaud Tachalerdmanee, Preeyanuch Perin, Fabrice |
Author_xml | – sequence: 1 givenname: Joël orcidid: 0000-0003-1941-4847 surname: Duperray fullname: Duperray, Joël email: jduperray@bcf-lifesciences.com organization: BCF Life Sciences – sequence: 2 givenname: Renaud surname: Sergheraert fullname: Sergheraert, Renaud organization: BCF Life Sciences – sequence: 3 givenname: Kunyanatt surname: Chalothorn fullname: Chalothorn, Kunyanatt organization: Spincontrol Asia Co., Ltd – sequence: 4 givenname: Preeyanuch surname: Tachalerdmanee fullname: Tachalerdmanee, Preeyanuch organization: Spincontrol Asia Co., Ltd – sequence: 5 givenname: Fabrice surname: Perin fullname: Perin, Fabrice organization: Spincontrol Asia Co., Ltd |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33834608$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtu1TAUhi1URB8wYQHIQ4S4xY88maELtKArdUAZW459Qtw6drAdVZcRS2BzbICV4JC2A4TwxP6Pv__48R-jA-cdIPSUklOax6srr_QpLSivH6AjWtR8w2hVHtyvOTlExzFeEULrlpaP0CHnDS8q0hyhn5cDYOh7UCli3-OUpQ_S4jhPk4URXJLJeLfs7X59_7Hdx2QcYBmjV0Ym0PjGpAEH0LPKYmHO7JxNQ3bBoj6d4-wf5lE6HK-Nw5P5ct_3NZY4SKf9aL6Bfom1nzu72DprnF4qHTg1jDJc5yLOJJ6sVND5LJV3KXhr87kq40ble6dgpH2MHvbSRnhyO5-gz-_fXW7PN7uLsw_bN7uN4qytN1o20OuqBs4p7UuiqoqUBdclK1VNaEnquq0q2uZRtk3RsZaxopNNCaovetbxE_R87TsF_3WGmMRoogJrpQM_R8FKShlv65Zl9NktOncjaDEFkx-1F3dRZICsgAo-xgC9UGb9oxSksYISsaQtlrTFn7Sz5cVflruu_4TpCt8YC_v_kOLjxfbt6vkNCb7DjA |
CitedBy_id | crossref_primary_10_1016_j_indcrop_2024_120363 crossref_primary_10_1039_D2TA08783A crossref_primary_10_1002_anie_202312728 crossref_primary_10_3390_antiox11030503 crossref_primary_10_1111_1365_2435_14209 crossref_primary_10_1186_s43094_023_00523_y crossref_primary_10_1097_JTCCM_D_24_00030 crossref_primary_10_1111_jdv_19717 crossref_primary_10_1111_jocd_15242 crossref_primary_10_7759_cureus_78045 crossref_primary_10_1038_s41467_022_34716_5 crossref_primary_10_1016_j_arr_2025_102712 crossref_primary_10_1111_jocd_16626 crossref_primary_10_7759_cureus_40892 crossref_primary_10_1016_j_ad_2022_09_014 crossref_primary_10_1002_ange_202312728 crossref_primary_10_3390_cosmetics12010027 crossref_primary_10_3390_cosmetics10050143 crossref_primary_10_1016_j_ad_2022_09_021 crossref_primary_10_1111_ijd_17535 crossref_primary_10_1136_lupus_2024_001401 crossref_primary_10_52660_JKSC_2023_29_6_1496 |
Cites_doi | 10.1111/1523-1747.ep12340980 10.1111/ijd.12999 10.3109/09546631003801619 10.1111/j.1755-148X.2009.00610.x 10.4103/0378-6323.179088 10.1002/jbio.200900066 10.1111/1523-1747.ep12365591 10.2147/CCID.S128339 10.1111/j.1468-2494.2010.00616.x 10.1111/1523-1747.ep12277369 10.1111/j.1600-0749.2006.00293.x 10.9734/EJNFS/2019/45634 10.1111/pcmr.12393 10.1007/s00726-011-0867-5 10.1590/S0365-05962013000100009 10.1111/pcmr.12235 10.1034/j.1600-0749.2003.00082.x 10.1111/1523-1747.ep12371709 10.1002/mnfr.201500031 10.1364/OL.28.000114 10.1111/jocd.12910 10.1038/sj.jid.5700683 10.2147/CCID.S115519 10.1093/jn/134.3.489 10.1016/j.jaad.2018.08.035 10.1364/OE.17.014599 10.4103/0378-6323.120752 10.1097/MCO.0b013e32834c1780 10.1046/j.1467-2494.2003.00182.x 10.1111/j.1467-2494.2005.00235.x 10.1002/lsm.20219 10.1111/pcmr.12121 |
ContentType | Journal Article |
Copyright | 2021 Wiley Periodicals LLC 2021 Wiley Periodicals LLC. |
Copyright_xml | – notice: 2021 Wiley Periodicals LLC – notice: 2021 Wiley Periodicals LLC. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1111/jocd.14137 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1473-2165 |
EndPage | 813 |
ExternalDocumentID | 33834608 10_1111_jocd_14137 JOCD14137 |
Genre | article Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: BCF Life Sciences |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 1OC 24P 29K 31~ 33P 36B 3SF 4.4 50Y 50Z 52M 52O 52T 52U 52V 52W 53G 5GY 5HH 5VS 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANHP AAONW AASGY AAXRX AAZKR ABCUV ABDBF ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCMX ACCZN ACGFS ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADPDF ADXAS ADZCM ADZMN AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFGKR AFKRA AFPWT AFZJQ AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMXJE BROTX BRXPI C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F D-I DCZOG DPXWK DRFUL DRMAN DRSTM EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F21 F5P FEDTE FUBAC FYUFA G-S G.N GODZA H.X HF~ HMCUK HVGLF HZ~ IHE KBYEO LATKE LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N04 N05 NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PIMPY Q.N QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 UKHRP V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WVDHM YFH YUY ZZTAW ~IA ~WT AAYXX AGQPQ CITATION PHGZM PHGZT AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c3297-da8efd67e3311f50c660543d525c7015077966199995984b29224ba85ecf4f2b3 |
ISSN | 1473-2130 1473-2165 |
IngestDate | Fri Jul 11 01:49:45 EDT 2025 Mon Jul 21 05:57:48 EDT 2025 Thu Apr 24 22:57:51 EDT 2025 Tue Jul 01 02:37:39 EDT 2025 Wed Jan 22 16:27:29 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | pheomelanin L-Cystine L-Glutathione oral supplementation skin pigmentation eumelanin |
Language | English |
License | 2021 Wiley Periodicals LLC. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3297-da8efd67e3311f50c660543d525c7015077966199995984b29224ba85ecf4f2b3 |
Notes | Funding information This study was fully funded and supported by BCF Life Sciences. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0003-1941-4847 |
PMID | 33834608 |
PQID | 2511239792 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2511239792 pubmed_primary_33834608 crossref_citationtrail_10_1111_jocd_14137 crossref_primary_10_1111_jocd_14137 wiley_primary_10_1111_jocd_14137_JOCD14137 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2022 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: February 2022 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of cosmetic dermatology |
PublicationTitleAlternate | J Cosmet Dermatol |
PublicationYear | 2022 |
References | 2009; 22 2019; 9 2013; 26 2007; 127 2019; 5 2013; 88 2014; 27 2011; 33 2008; 35 2006; 19 2003; 16 2019; 18 2011; 14 2005; 27 1996; 107 1993; 101 2016; 55 2004; 134 1989; 93 2019; 80 2015; 28 1997; 109 2013; 79 2017; 10 2011; 42 2003; 25 2003; 28 2016; 60 2016; 82 2010; 3 2005; 37 2012; 23 2016; 9 2009; 17 e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_35_1 e_1_2_11_12_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 Nobile V (e_1_2_11_33_1) 2019; 5 Li EPH (e_1_2_11_2_1) 2008; 35 e_1_2_11_21_1 e_1_2_11_20_1 e_1_2_11_25_1 e_1_2_11_24_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_19_1 |
References_xml | – volume: 33 start-page: 210 issue: 3 year: 2011 end-page: 221 article-title: The melanogenesis and mechanisms of skin‐lightening agents – existing and new approaches publication-title: Int J Cosmet Sci – volume: 27 start-page: 512 issue: 4 year: 2014 end-page: 524 article-title: The biology of hyperpigmentation syndromes publication-title: Pigment Cell Melanoma Res – volume: 27 start-page: 147 issue: 3 year: 2005 end-page: 153 article-title: Glutathione as a depigmenting agent: an overview publication-title: Int J Cosmet Sci – volume: 23 start-page: 97 issue: 2 year: 2012 end-page: 102 article-title: Glutathione as an oral whitening agent: a randomized, double‐blind, placebo‐controlled study publication-title: J Dermatol Treat – volume: 9 start-page: 22 issue: 1 year: 2019 end-page: 24 article-title: Risk assessment of “other substances” – L‐cysteine and L‐cystine publication-title: Eur J Nutr Food Safety – volume: 9 start-page: 325 year: 2016 end-page: 332 article-title: Overall skin tone and skin‐lightening‐improving effects with oral supplementation of lutein and zeaxanthin isomers: a double‐blind, placebo controlled clinical trial publication-title: Clin Cosm Invest Dermatol – volume: 17 start-page: 14599 issue: 17 year: 2009 end-page: 14617 article-title: Chromophore concentrations, absorption and scattering properties of human skin publication-title: Opt Express – volume: 127 start-page: 751 issue: 4 year: 2007 end-page: 761 article-title: Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase publication-title: J Invest Dermatol – volume: 37 start-page: 138 issue: 2 year: 2005 end-page: 143 article-title: Determination of an optimized conversion matrix for device independent skin color image analysis publication-title: Lasers Surg Med – volume: 19 start-page: 154 issue: 2 year: 2006 end-page: 162 article-title: Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin publication-title: Pigment Cell Res – volume: 28 start-page: 520 issue: 5 year: 2015 end-page: 544 article-title: Melanins and melanogenesis: from pigment cells to human health and technological applications publication-title: Pigment Cell Melanoma Res – volume: 18 start-page: 728 issue: 3 year: 2019 end-page: 737 article-title: The clinical effect of glutathione on skin color and other related skin conditions: a systematic review publication-title: J Cosmet Dermatol – volume: 88 start-page: 76 issue: 1 year: 2013 end-page: 83 article-title: Mechanisms regulating melanogenesis publication-title: An Bra Dermatol – volume: 26 start-page: 616 issue: 5 year: 2013 end-page: 633 article-title: Melanins and melanogenesis: methods, standards, protocols publication-title: Pigment Cell Melanoma Res – volume: 107 start-page: 698 issue: 5 year: 1996 end-page: 702 article-title: Cysteine deprivation promotes eumelanogenesis in human melanoma cells publication-title: J Invest Dermatol – volume: 42 start-page: 231 issue: 1 year: 2011 end-page: 246 article-title: The oxidative stress‐inducible Cystine/Glutamate antiporter, system X (c) (‐): cystine supplier and beyond publication-title: Amino Acids – volume: 16 start-page: 487 issue: 5 year: 2003 end-page: 493 article-title: Rate constants for the first two chemical steps of eumelanogenesis publication-title: Pigment Cell Res – volume: 60 start-page: 134 issue: 1 year: 2016 end-page: 146 article-title: L‐Cysteine metabolism and its nutritional implication publication-title: Mol Nutr Food Res – volume: 101 start-page: 871 issue: 6 year: 1993 end-page: 874 article-title: Glutathione depletion increases tyrosinase activity in human melanoma cells publication-title: J Invest Dermatol – volume: 14 start-page: 562 issue: 6 year: 2011 end-page: 568 article-title: Clinical and nutritional benefits of cysteine‐enriched protein supplements publication-title: Curr Opin Clin Nutr Metab Care – volume: 134 start-page: 489 issue: 3 year: 2004 end-page: 492 article-title: Glutathione metabolism and its implication for health publication-title: J Nutr – volume: 10 start-page: 147 year: 2017 end-page: 153 article-title: Glutathione and its antiaging and antimelanogenic effects publication-title: Clin Cosmet Inves. Dermatol – volume: 28 start-page: 114 issue: 2 year: 2003 end-page: 116 article-title: Surface‐reflection elimination in polarization imaging of superficial tissue publication-title: Opt Letters – volume: 25 start-page: 169 issue: 4 year: 2003 end-page: 181 article-title: Skin‐lightening products revisited publication-title: Int J Cosmet Sci – volume: 35 start-page: 444 year: 2008 end-page: 449 article-title: Skin lightening and beauty in four Asian cultures publication-title: Adv Consumer Res – volume: 3 start-page: 15 issue: 1‐2 year: 2010 end-page: 24 article-title: Interpreting diffuse reflectance for skin reactions in terms of chromophores publication-title: J Biophotonics – volume: 5 start-page: 142 issue: 1 year: 2019 end-page: 150 article-title: Efficacy and safety of L‐Cystine associated or not to a natural keratin (Kera‐Diet ) hydrolysate on hair and nails: randomized, placebo‐controlled, clinical trial on healthy females publication-title: J Cosmo Trichol – volume: 55 start-page: 153 issue: 2 year: 2016 end-page: 157 article-title: An open‐label, single‐arm trial of the safety and efficacy of a novel preparation of glutathione as a skin‐lightening agent in Filipino women publication-title: Int J Dermatol – volume: 80 start-page: 1564 issue: 6 year: 2019 end-page: 1584 article-title: Developing an international standard for the classification of surface anatomic location for use in clinical practice and epidemiologic research publication-title: J Am Acad Dermatol – volume: 93 start-page: 100 issue: 1 year: 1989 end-page: 107 article-title: Analysis of initial melanogenesis including tyrosinase transfer and melanosome differentiation through interrupted melanization by glutathione publication-title: J Invest Dermatol – volume: 109 start-page: 796 issue: 6 year: 1997 end-page: 800 article-title: Melanogenesis in cultured melanocytes can be substantially influenced by L‐Tyrosine and L‐Cysteine publication-title: J Invest Dermatol – volume: 79 start-page: 842 issue: 6 year: 2013 end-page: 846 article-title: Systemic skin whitening/lightening agents: what is the evidence? publication-title: Indian J Dermatol Venereol Leprol – volume: 82 start-page: 262 issue: 3 year: 2016 end-page: 272 article-title: Glutathione as a skin whitening agent: facts, myths, evidence and controversies publication-title: Indian J Dermatol Venereol Leprol – volume: 22 start-page: 563 issue: 5 year: 2009 end-page: 579 article-title: Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function publication-title: Pigment Cell Melanoma Res – ident: e_1_2_11_18_1 doi: 10.1111/1523-1747.ep12340980 – ident: e_1_2_11_27_1 doi: 10.1111/ijd.12999 – ident: e_1_2_11_26_1 doi: 10.3109/09546631003801619 – ident: e_1_2_11_8_1 doi: 10.1111/j.1755-148X.2009.00610.x – volume: 35 start-page: 444 year: 2008 ident: e_1_2_11_2_1 article-title: Skin lightening and beauty in four Asian cultures publication-title: Adv Consumer Res – ident: e_1_2_11_19_1 doi: 10.4103/0378-6323.179088 – ident: e_1_2_11_3_1 doi: 10.1002/jbio.200900066 – ident: e_1_2_11_14_1 doi: 10.1111/1523-1747.ep12365591 – ident: e_1_2_11_20_1 doi: 10.2147/CCID.S128339 – ident: e_1_2_11_6_1 doi: 10.1111/j.1468-2494.2010.00616.x – ident: e_1_2_11_12_1 doi: 10.1111/1523-1747.ep12277369 – volume: 5 start-page: 142 issue: 1 year: 2019 ident: e_1_2_11_33_1 article-title: Efficacy and safety of L‐Cystine associated or not to a natural keratin (Kera‐Diet®) hydrolysate on hair and nails: randomized, placebo‐controlled, clinical trial on healthy females publication-title: J Cosmo Trichol – ident: e_1_2_11_10_1 doi: 10.1111/j.1600-0749.2006.00293.x – ident: e_1_2_11_34_1 doi: 10.9734/EJNFS/2019/45634 – ident: e_1_2_11_31_1 doi: 10.1111/pcmr.12393 – ident: e_1_2_11_29_1 doi: 10.1007/s00726-011-0867-5 – ident: e_1_2_11_7_1 doi: 10.1590/S0365-05962013000100009 – ident: e_1_2_11_32_1 doi: 10.1111/pcmr.12235 – ident: e_1_2_11_15_1 doi: 10.1034/j.1600-0749.2003.00082.x – ident: e_1_2_11_13_1 doi: 10.1111/1523-1747.ep12371709 – ident: e_1_2_11_16_1 doi: 10.1002/mnfr.201500031 – ident: e_1_2_11_23_1 doi: 10.1364/OL.28.000114 – ident: e_1_2_11_35_1 doi: 10.1111/jocd.12910 – ident: e_1_2_11_5_1 doi: 10.1038/sj.jid.5700683 – ident: e_1_2_11_25_1 doi: 10.2147/CCID.S115519 – ident: e_1_2_11_17_1 doi: 10.1093/jn/134.3.489 – ident: e_1_2_11_22_1 doi: 10.1016/j.jaad.2018.08.035 – ident: e_1_2_11_4_1 doi: 10.1364/OE.17.014599 – ident: e_1_2_11_11_1 doi: 10.4103/0378-6323.120752 – ident: e_1_2_11_28_1 doi: 10.1097/MCO.0b013e32834c1780 – ident: e_1_2_11_21_1 doi: 10.1046/j.1467-2494.2003.00182.x – ident: e_1_2_11_9_1 doi: 10.1111/j.1467-2494.2005.00235.x – ident: e_1_2_11_24_1 doi: 10.1002/lsm.20219 – ident: e_1_2_11_30_1 doi: 10.1111/pcmr.12121 |
SSID | ssj0017915 |
Score | 2.3633263 |
Snippet | Background
Glutathione has become a potential skin‐lightening ingredient after the discovery of its anti‐melanogenic properties. Various mechanisms of action... Glutathione has become a potential skin-lightening ingredient after the discovery of its anti-melanogenic properties. Various mechanisms of action have been... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 802 |
SubjectTerms | Cystine - therapeutic use Double-Blind Method eumelanin Female Glutathione - therapeutic use Humans L‐Cystine L‐Glutathione oral supplementation pheomelanin skin pigmentation Skin Pigmentation - drug effects |
Title | The effects of the oral supplementation of L‐Cystine associated with reduced L‐Glutathione‐GSH on human skin pigmentation: a randomized, double‐blinded, benchmark‐ and placebo‐controlled clinical trial |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjocd.14137 https://www.ncbi.nlm.nih.gov/pubmed/33834608 https://www.proquest.com/docview/2511239792 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1473-2165 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017915 issn: 1473-2130 databaseCode: ABDBF dateStart: 20020901 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVOVD databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling customDbUrl: eissn: 1473-2165 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017915 issn: 1473-2130 databaseCode: OVEED dateStart: 20020101 isFulltext: true titleUrlDefault: http://ovidsp.ovid.com/ providerName: Ovid |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdKJyFeEN-ULxmBkIB5apM0H7xB260a3YqgQ32LnNiBaW1T0uZh-w_5q-DOdt2WdmjwEqWuGye9X3x39u_uCHnp-sKtC5AAjwKXeaIhGBeZz7wEJkJU2NLFAOejY7974h0Om8NK5dcKa6mcJ3vpxda4kv-RKrSBXDFK9h8kay8KDXAO8oUjSBiOV5bxCiEDbUgVcD_DUp2aFr4wCHusdQ5vM5iU3AhkwTsvMHkrfOixA7hXJCPmE8kOvnRxH0GX8JudIdf89Ju9og6RBjUn8vHphV4vFXmZjCRLRpiAUbUk8F99H_PijOl0BLhin-TMsONHMKaNy1TFQy4xlNN8NsZQy7cCtch8bR-gXU5lUXBddjlXu_4fLGcE5kEksXATlvRZTngpVvgMI0BprsnMH8vJOZ_wuSUBDXgKHWQh4Pk1V-lTISX0Kc3Sn1kpASe7blknenL3AI5OQ9em2JNb2oxGcBoryHdWpvdQRYdfqnbyVIDmaegsNuu5vY_78f5JrxcPOsPBq-kPhmXPkB5gasBcIztO4PtOlez0v3Y6bbsRFkSqCIe9TZNhV5HR7HDrNtWGo7TudynDaXCL3DSCpO81fG-TipzcIdePDKfjLvkJKKYGxTTPKKCYIorpHyjG7yyK6RLFFFFMDYrpBoop_FKhmCKK6SqK31FOlxjepesI3qVL_FLoRTfxSxf4pQq_98jJfmfQ6jJTYISlrhMFTPBQZsIPpOs2Glmznvrg3HuuaDrNNMClwCCIwH4FHypqRqGXOBEYvAkPmzLNvMxJ3PukOoGneUhoKASPfPB-Ei_xhIhCN8gCrx5yTzpBlEU18nohojg12fexCMwotl44iDNW4qyRF7bvVOec2drr-ULSMagE3OeDFyIvZzGuGji4X-_UyAMNAXsdXJHy_HpYI28UJv4yQHzYb7XV2aMrDPWY3Fi-c09IdV6U8inY6_PkmcH0byE_9rc |
linkProvider | Ovid |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+the+oral+supplementation+of+L-Cystine+associated+with+reduced+L-Glutathione-GSH+on+human+skin+pigmentation%3A+a+randomized%2C+double-blinded%2C+benchmark-+and+placebo-controlled+clinical+trial&rft.jtitle=Journal+of+cosmetic+dermatology&rft.au=Duperray%2C+Jo%C3%ABl&rft.au=Sergheraert%2C+Renaud&rft.au=Chalothorn%2C+Kunyanatt&rft.au=Tachalerdmanee%2C+Preeyanuch&rft.date=2022-02-01&rft.issn=1473-2165&rft.eissn=1473-2165&rft.volume=21&rft.issue=2&rft.spage=802&rft_id=info:doi/10.1111%2Fjocd.14137&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-2130&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-2130&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-2130&client=summon |